Biotech Stocks: short review to Gilead Science biotechnology company, stocks and market in 2022

Gilead science is one of the pioneer international biotechnology companies concentrating on new drugs and biopharmaceuticals products.

Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Gilead Science stock price known as GILD in NASDAQ in January is about 67.87 USD.

Gilead Sciences (NASDAQ:GILD) is known for several things. It’s a leader in developing HIV drugs such as Truvada and Genvoya. The company’s drugs Sovaldi, Harvoni, and Epclusa have changed the landscape in treatment of hepatitis C. Gilead is now one of the biggest biotechs in the world.

70% of Gilead Sciences employees would recommend working there to a friend based on Glassdoor reviews. Employees also rated Gilead Sciences 3.2 out of 5 for work life balance, 3.6 for culture and values and 3.4 for career opportunities.

Gilead Sciences is not owned by hedge funds. Capital Research and Management Company is currently the company’s largest shareholder with 16% of shares outstanding. In comparison, the second and third largest shareholders hold about 8.8% and 8.2% of the stock.

Gilead Sciences CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home. O’Day came into his role at Gilead in March of 2019, scoring $29.1 million in compensation.

Leave a Reply

Your email address will not be published.